Mizuho Securities Keeps Their Buy Rating on Endo International

By Ryan Adsit

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Endo International (NASDAQ: ENDP), with a price target of $19. The company’s shares closed yesterday at $12.78.

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 18.9% and a 53.7% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Apricus Biosciences Inc, Sucampo Pharmaceuticals, and Pacira Pharmaceuticals.

Endo International has an analyst consensus of Hold, with a price target consensus of $16.

The company has a one year high of $24.93 and a one year low of $9.70. Currently, Endo International has an average volume of 9.2M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded on October 31, 2013 and is headquartered Dublin, Ireland.